Cohen MH - Search Results

1

FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease.

Lu M, Cohen MH, Rieves D, Pazdur R. Lu M, et al. Among authors: cohen mh. Am J Hematol. 2010 May;85(5):315-9. doi: 10.1002/ajh.21656. Am J Hematol. 2010. PMID: 20201089 Clinical Trial.

2

Approval summary: Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancer.

Cohen MH, Chen H, Shord S, Fuchs C, He K, Zhao H, Sickafuse S, Keegan P, Pazdur R. Cohen MH, et al. Oncologist. 2013;18(4):460-6. doi: 10.1634/theoncologist.2012-0458. Epub 2013 Apr 10. Oncologist. 2013. PMID: 23576486 Free PMC article.

3

U.S. Food and Drug Administration Approval: peginterferon-alfa-2b for the adjuvant treatment of patients with melanoma.

Herndon TM, Demko SG, Jiang X, He K, Gootenberg JE, Cohen MH, Keegan P, Pazdur R. Herndon TM, et al. Among authors: cohen mh. Oncologist. 2012;17(10):1323-8. doi: 10.1634/theoncologist.2012-0123. Epub 2012 Sep 21. Oncologist. 2012. PMID: 23002124 Free PMC article. Clinical Trial.

4

Approval summary: imatinib mesylate for one or three years in the adjuvant treatment of gastrointestinal stromal tumors.

Cohen MH, Johnson JR, Justice R, Pazdur R. Cohen MH, et al. Oncologist. 2012;17(7):992-7. doi: 10.1634/theoncologist.2012-0109. Epub 2012 May 29. Oncologist. 2012. PMID: 22643537 Free PMC article. Clinical Trial.

5

Approval summary: letrozole (Femara® tablets) for adjuvant and extended adjuvant postmenopausal breast cancer treatment: conversion of accelerated to full approval.

Cohen MH, Johnson JR, Justice R, Pazdur R. Cohen MH, et al. Oncologist. 2011;16(12):1762-70. doi: 10.1634/theoncologist.2011-0287. Epub 2011 Nov 16. Oncologist. 2011. PMID: 22089970 Free PMC article. Review.

6

Approval summary: pemetrexed maintenance therapy of advanced/metastatic nonsquamous, non-small cell lung cancer (NSCLC).

Cohen MH, Cortazar P, Justice R, Pazdur R. Cohen MH, et al. Oncologist. 2010;15(12):1352-8. doi: 10.1634/theoncologist.2010-0224. Epub 2010 Dec 10. Oncologist. 2010. PMID: 21148615 Free PMC article. Clinical Trial.

7

Approval summary: erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC).

Cohen MH, Johnson JR, Chattopadhyay S, Tang S, Justice R, Sridhara R, Pazdur R. Cohen MH, et al. Oncologist. 2010;15(12):1344-51. doi: 10.1634/theoncologist.2010-0257. Epub 2010 Dec 10. Oncologist. 2010. PMID: 21148614 Free PMC article. Clinical Trial.

8

Approval summary: imatinib mesylate in the adjuvant treatment of malignant gastrointestinal stromal tumors.

Cohen MH, Cortazar P, Justice R, Pazdur R. Cohen MH, et al. Oncologist. 2010;15(3):300-7. doi: 10.1634/theoncologist.2009-0120. Epub 2010 Mar 3. Oncologist. 2010. PMID: 20200041 Free PMC article. Clinical Trial.

9

FDA drug approval summary: bevacizumab plus interferon for advanced renal cell carcinoma.

Summers J, Cohen MH, Keegan P, Pazdur R. Summers J, et al. Among authors: cohen mh. Oncologist. 2010;15(1):104-11. doi: 10.1634/theoncologist.2009-0250. Epub 2010 Jan 8. Oncologist. 2010. PMID: 20061402 Free PMC article.

10

FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme.

Cohen MH, Shen YL, Keegan P, Pazdur R. Cohen MH, et al. Oncologist. 2009 Nov;14(11):1131-8. doi: 10.1634/theoncologist.2009-0121. Epub 2009 Nov 6. Oncologist. 2009. PMID: 19897538

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results